KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Discontinued Operations: 2021-2024

Historic Cash from Discontinued Operations for TherapeuticsMD (TXMD) over the last 4 years, with Dec 2024 value amounting to -$438,000.

  • TherapeuticsMD's Cash from Discontinued Operations rose 141.23% to $47,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$28,000, marking a year-over-year increase of 99.16%. This contributed to the annual value of -$438,000 for FY2024, which is 98.25% up from last year.
  • Latest data reveals that TherapeuticsMD reported Cash from Discontinued Operations of -$438,000 as of FY2024, which was up 98.25% from -$25.1 million recorded in FY2023.
  • TherapeuticsMD's Cash from Discontinued Operations' 5-year high stood at $210.4 million during FY2022, with a 5-year trough of -$87.6 million in FY2021.
  • For the 3-year period, TherapeuticsMD's Cash from Discontinued Operations averaged around $61.6 million, with its median value being -$438,000 (2024).
  • As far as peak fluctuations go, TherapeuticsMD's Cash from Discontinued Operations spiked by 340.29% in 2022, and later tumbled by 111.91% in 2023.
  • Yearly analysis of 4 years shows TherapeuticsMD's Cash from Discontinued Operations stood at -$87.6 million in 2021, then soared by 340.29% to $210.4 million in 2022, then slumped by 111.91% to -$25.1 million in 2023, then surged by 98.25% to -$438,000 in 2024.